Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAkdeniz, Cansu Selcan
dc.contributor.authorCevik, Mehtap
dc.contributor.authorCanbolat, Ismail Polat
dc.contributor.authorYurdakul, Selen
dc.contributor.authorCagatay, Penbe
dc.contributor.authorCiftci, Cavlan
dc.contributor.authorKaraalp, Atila
dc.date.accessioned2021-06-10T19:38:38Z
dc.date.available2021-06-10T19:38:38Z
dc.date.issued2020
dc.identifier.issn1479-6678
dc.identifier.issn1744-8298
dc.identifier.urihttps://doi.oeg/10.2217/fca-2020-0027
dc.identifier.urihttp://hdl.handle.net/11446/4392
dc.descriptionKaraalp, Atila/0000-0003-3382-9483en_US
dc.descriptionPubMed: 32583677en_US
dc.descriptionWOS:000614216900012en_US
dc.description.abstractAim: Our aim was to examine the effect of CYP2C9 and VKORC1 polymorphisms on warfarin dose requirements in Turkish patients. Materials & methods: 24 warfarin prescribed patients were included and analyzed for eight VKORC1 and 6 CYP2C9 polymorphisms in the study. Results: Patients with CYP2C9 *1/*1 and VKORC1 -1639 GG and GA genotypes required higher warfarin doses in comparison to wild type VKORC1 genotype. Patients with CYP2C9 *1/*3 and VKORC1 -1639 GG genotypes simultaneously, required the lowest dose of warfarin (4.64 mg/day). Patients with CYP2C9 *1/*1 and VKORC1 9041 AA genotype were found to require higher warfarin doses. Conclusion: Our results provide additional evidence to support the hypothesis that CYP2C9 *2, *3, VKORC1 9041 G > A polymorphisms explain considerable proportion of inter-individual variability in warfarin dose requirement.en_US
dc.description.sponsorshipIstanbul Development AgencyTurkiye Cumhuriyeti Kalkinma Bakanligi [TR10/16/YNY/0030]en_US
dc.description.sponsorshipThis study was supported by Istanbul Development Agency, Project No. TR10/16/YNY/0030. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.language.isoengen_US
dc.publisherFuture Medicine Ltden_US
dc.identifier.doi10.2217/fca-2020-0027en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject9041 G > Aen_US
dc.subjectCYP2C9en_US
dc.subjectpharmacogeneticsen_US
dc.subjectVKORC1en_US
dc.subjectwarfarinen_US
dc.titleThe effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patientsen_US
dc.typearticleen_US
dc.relation.journalFuture Cardiologyen_US
dc.department[0-Belirlenecek]en_US
dc.identifier.issue6en_US
dc.identifier.volume16en_US
dc.identifier.startpage645en_US
dc.identifier.endpage654en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthor[0-Belirlenecek]
dc.department-temp[Akdeniz, Cansu Selcan; Canbolat, Ismail Polat; Yurdakul, Selen; Ciftci, Cavlan] Demiroglu Bilim Univ, Fac Med, Dept Cardiol, Istanbul, Turkey; [Cevik, Mehtap; Susleyici, Belgin] Marmara Univ, Fac Sci & Letters, Dept Mol Biol, Istanbul, Turkey; [Cagatay, Penbe] Istanbul Univ Cerrahpasa, Dept Med Serv & Tech, Vocat Sch Hlth Serv, Istanbul, Turkey; [Karaalp, Atila] Marmara Univ, Sch Med, Dept Med Pharmacol, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster